Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

Key facts

Sponsor

Duke University

Principal Investigator

Thomas L. Ortel, MD, PhD

Duke University

Enrollment

2800 enrolled

Eligibility

All sexes

Timeline

2006 – 2028

Study locations (1)

• Duke University Medical Center, Durham, North Carolina, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07372170
  Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients
  Infanta Leonor University Hospital
• RECRUITINGNANCT07163338
  Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)
  CHU de Reims
• RECRUITINGNANCT06373926
  Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
  Centre Hospitalier Universitaire, Amiens
• ENROLLING BY INVITATIONPHASE1NCT06723106
  Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
  Chugai Pharmaceutical
• RECRUITINGNCT06373003
  Negative Antiphospholipid Syndrome: a Multicentric Study
  Italian Society for Rheumatology
• RECRUITINGPHASE1NCT06371417
  Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
  Chugai Pharmaceutical
• RECRUITINGPHASE2NCT06747312
  Effect of Belimumab on Antibody Titers in Primary APS Patients
  Ruijin Hospital
• RECRUITINGPHASE4NCT05995600
  Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
  Seoul National University Hospital

See all trials for Antiphospholipid syndrome →